DRUG INFORMATION ASSOCIATION

June 17-21, 2007 | Atlanta, Georgia

Don't miss the event of the year for the pharmaceutical and related industries!

Attend presentations and case studies from more than 1,000 speakers

Hear representatives from the FDA, EMEA and other global regulatory agencies

27 tracks offered over 3½ days

35+ preconference tutorials

Over 450 exhibitors
Exhibit space is still available!

43rd Annual Meeting

Georgia World Congress Center

PROGRAM CHAIRPERSON

Alberto Grignolo, PhD

PAREXEL Consulting

Program Chairperson

Alberto Grignolo, PhD

Alberto Grignolo, PhD, is Corporate Vice President and General Manager of the Drug Development Consulting Practice in PAREXEL Consulting. For the past fourteen years he has been responsible for PAREXEL's regulatory services, including worldwide drug development consulting and registration strategies and submissions, regulatory compliance and clinical quality assurance for pharmaceuticals, biologics and medical devices. He leads a worldwide staff of professional consultants and advises clients in the areas of drug development strategy, regulatory negotiation and best regulatory practices.

Prior to joining PAREXEL, Dr. Grignolo served as President of FIDIA Pharmaceutical Corporation and held regulatory positions at SmithKline & French Laboratories. Having completed his undergraduate degree at Duke University, he earned his doctorate in Experimental Psychology from the University of North Carolina and conducted postdoctoral research in neuropharmacology at Duke University Medical Center.

He is a past Chairman of the Board of the Regulatory Affairs Professionals Society (RAPS), has been involved in the advancement of the regulatory profession for most of his career and was the recipient of the 1995 Richard E. Greco Professional of the Year from RAPS. He has been an active member of DIA since 1984, served on the board of DIA from 2000 until 2004, was the Chair of the Regulatory Track of the 2001, 2002, 2003 DIA Annual Meetings and is an Instructor on the DIA Regulatory Training Faculty.

He serves on the Graduate Faculty of the Massachusetts College of Pharmacy and Health Sciences in Boston as an Adjunct Associate Professor, and was an Expert Advisor to the Institute of Medicine's "Committee on Assessing the System for Protecting Human Research Participants" in 2000-2002.

A native European who has also lived in Latin America and speaks four languages, Dr. Grignolo is a frequent speaker, instructor and participant at international conferences, seminars, workshops and courses on Drug Development, Regulatory Affairs and Good Clinical Practice.

Schoolchildren and mathematicians know that 43 is a "prime number" – one that can only be divided by 1 and by itself. Other than that, the number 43 is not particularly interesting or special. The 43rd wedding anniversary is not even associated with a stone (precious or not). Turning 40 is a major, often traumatic milestone for many people; but turning 43 just makes you glad that you are still a long way from 50!

And so here we are, looking ahead to the 43rd Annual Meeting of DIA. This means that the ***first*** Annual Meeting was held in 1964. Think about that. Many of us were teenagers then; many who will attend this Annual Meeting had not been born yet. Beatlemania and the Cold War were all the rage. The European Community was 7 years old and had only 6 Member States. The concept of the IND was 2 years old.

Forty-three years later, the world is rather different – including that particular, specialized pharmaceutical world that DIA has mirrored and influenced for more than four decades. Through the yearly gathering of thousands of its members, DIA's Annual Meeting has chronicled events of profound impact to the development of medicines; has offered a forum to innovators, critics, thought leaders, regulators and students of our field; has attracted and nurtured an ever-expanding multinational constituency; has become the must-attend event of the year for so many in our particular world.

Join us in Atlanta! Whether for the first time or the 43rd, you will reap the benefits of the imagination, dedication, and intellectual diversity of those who have labored to craft a program of vast breadth and complexity to stimulate you, engage you, challenge you, and inform you. We were fortunate to receive more than twice as many session abstracts as we can accommodate in four days. As a result, we, the Program Committee, have selected the best of the best in our quest for excellence, and have designed a meeting that is timely, topical, and transforming.

Dr. Julie Gerberding, Director of the Atlanta-based Centers for Disease Control (CDC), will deliver the Keynote Address. We will feature nearly 400 regular, plenary, and tutorial sessions with over 1,000 speakers; more than 450 exhibitors will help expand our awareness of services and technologies relevant to the interests of DIA members everywhere. Across 27 tracks, we will map for you such themes as FDA Critical Path, Global Clinical Trials, Personalized Medicine, India, Japan, and China to help you identify the sessions of greatest interest to you. Once again, to facilitate your personal scheduling, we will list all sessions on a website that will allow you to click on specific sessions and download their titles, times, and locations automatically to your Blackberry or PDA calendar! Throughout, the opportunities for making new friends and reconnecting with your established network will abound.

For the 43rd straight year, the content experts from industry, government, and academia and the phenomenal DIA staff have collaborated to bring you the best possible Annual Meeting program. The city of Atlanta, home of CNN, the CDC, the world's busiest airport, art, culture, glorious peaches, and innumerable attractions, awaits our arrival with exceptional and warm southern hospitality.

DIA 43rd in Atlanta – a prime number, a prime location! See you there!

Alberto Grignolo
2007 Annual Meeting Program Chairperson

Please monitor www.diahome.org for program updates and online registration.

♦ ACADEMIC HEALTH CENTERS
Stanley A. Edlavitch, PhD, MA
University of Missouri-Kansas City, USA
Melvyn Greberman, MD, MS, MPH
Public Health Resources, LLC, USA

♦ ADVERTISING
Neal Collins, MD
Pfizer Inc, USA
John F. Kamp, JD, PhD
Coalition for Healthcare Communication, USA
Wayne L. Pines
APCO Worldwide, USA

♦ BIOTECHNOLOGY
Joy A. Cavagnaro, PhD
Access BIO, USA
Bernard D. "Barney" King, MD, MBA
Macnas Consulting International, USA

♦ CHEMISTRY, MANUFACTURING, AND CONTROLS/GOOD MANUFACTURING PRACTICES
Chi-wan Chen, PhD
FDA, USA
Charles P. Hoiberg, PhD
Pfizer Inc, USA

♦ CLINICAL DATA MANAGEMENT
Jonathan Haddad, MPH
Synta Pharmaceuticals Corp., USA

♦ CLINICAL RESEARCH AND DEVELOPMENT
Larry A. Blankstein, PhD
Genzyme Corp., USA
Craig Lipset, MPH
Pfizer Inc, USA

♦ CLINICAL SAFETY AND PHARMACOVIGILANCE
Brian D. Edwards
Johnson & Johnson PRD, UK
Arnold J. Gordon, PhD, MS
Pharmaceutical Consultant, USA
Annette Stemhagen, DrPH, MPH
United Biosource Corp., USA

♦ CLINICAL TRIAL MANAGEMENT/ CLINICAL SUPPLIES
Patricia A. Moore, MBA
Genentech, USA

♦ ELECTRONIC REGULATORY SUBMISSIONS/ DOCUMENT MANAGEMENT
A. Kay Bross, MEd
Procter & Gamble Co., USA
Mary L. Collins
Image Solutions, Inc., USA

♦ eCLINICAL
Charles Jaffe, MD, PhD
Intel Corporation, USA

♦ GOOD CLINICAL PRACTICES
Michael R. Hamrell, PhD
MORIAH Consultants, USA
Beat E. Widler, PhD
Roche Products Ltd., UK

♦ IMPACT OF MEDICAL PRODUCTS AND THERAPIES
C. Daniel Mullins, PhD
University of Maryland School of Pharmacy, USA

♦ INFORMATION TECHNOLOGY
Paul A. Bleicher, MD, PhD
Phase Forward, USA
Barbara E. Tardiff, MD, MBA, MS
Merck & Co., Inc., USA
Srinivas Vangala
Forest Research Institute, USA

♦ INVESTIGATOR SITES
Karen E. Woodin, PhD
JKK Consulting LLC, USA

♦ MARKETING AND SALES
Douglas A. Reagan
iMetrikus, Inc., USA

♦ MEDICAL COMMUNICATIONS
Rebecca A. Vermeulen, RPH
Eli Lilly and Company, USA

♦ MEDICAL/SCIENTIFIC WRITING
Barbara R. Kamm
Allergan Inc., USA
Jean H. Soul-Lawton, DrPH
GlaxoSmithKline R&D, UK
Virginia I. Watson
Cardinal Health, UK

♦ NATURAL HEALTH PRODUCTS
Hubertus Cranz, PhD, PharmD, MS
AESGP, Belgium
Freddie Ann Hoffman, MD
HeteroGeneity, LLC, USA

♦ NONCLINICAL LABORATORY SAFETY ASSESSMENT
Joseph J. DeGeorge, PhD
Merck & Co., Inc., USA
Per Spindler, DVM, MSc, MBIRA
BioLogue/University of Copenhagen, Denmark

♦ OUTSOURCING
Gregory M. Hockel, PhD, MBA
PharmaNet, Inc., USA

♦ PROJECT MANAGEMENT/FINANCE
Martin D. Hynes, III, PhD
Eli Lilly and Company, USA
John Sun, PhD, MBA
sanofi-aventis, USA

♦ PUBLIC POLICY/LAW
John C. Marlow, MD
Advanstar Communications, Inc., USA
Peter H. Rheinstein, MD, JD, MS
Severn Health Solutions, USA

♦ REGULATORY AFFAIRS
Ian Laws
GlaxoSmithKline Pharmaceuticals, UK
Craig A. Metz, PhD
GlaxoSmithKline, USA
Robert A. Paarlberg, MS
UCB, Inc., USA
Lynne M. Tracey
P&G Pharmaceuticals, Inc., USA

♦ R&D STRATEGY
Kenneth I. Kaitin, PhD
Tufts Center for the Study of Drug Development, Tufts University, USA

♦ STATISTICS
Jerald S. Schindler, DrPH, PharmD
Cytel Pharmaceutical Research, USA
Stephen E. Wilson, DrPH, CAPT. USPHS
CDER, FDA, USA
Peiling Yang
FDA, USA

♦ TRAINING
Betty R. Kuhnert, PhD, MBA
Betty R. Kuhnert, PhD, MBA, LLC, USA
Monika M. Pietrek, MD, PhD, MSc
PRA International, Germany

♦ VALIDATION
Joanne S. Malia, MS
Neurogen Corporation, USA

Advisors:

EU/EMEA ISSUES
Daniel Brasseur, MD, PhD
CHMP Chairman
Ministry of Public Health, Belgium

FDA ISSUES
Nancy D. Smith, PhD
CDER, FDA, USA

HEALTH CANADA ISSUES
Agnes V. Klein, MD, DrPH
Health Canada, Canada

JAPAN ISSUES
Tatsuo Kurokawa, PhD
MHLW, Japan

Keynote Speaker

Julie Louise Gerberding, MD, MPH, is Director of the Centers for Disease Control and Prevention (CDC) and the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR).

Previously, Dr. Gerberding was Acting Deputy Director of the National Center for Infectious Diseases (NCID), where she played a major role in leading CDC's response to the anthrax bioterrorism events of 2001. She joined CDC in 1998 as Director of the Division of Healthcare Quality Promotion, NCID, where she developed CDC's patient safety initiatives and other programs to prevent infections, antimicrobial resistance, and medical errors in healthcare settings. Dr. Gerberding also served as a faculty member at the University of California at San Francisco (UCSF) where she directed the Prevention Epicenter, a multidisciplinary research, training, and clinical service program that focused on preventing infections in patients and their healthcare providers.

Dr. Gerberding is a member of Phi Beta Kappa, Alpha Omega Alpha (medical honor society), American Society for Clinical Investigation (ASCI), American College of Physicians, Infectious Diseases Society of America, the American Epidemiology Society, the National Academy of Public Administration, and the Institute of Medicine.

Over the course of her career, Dr. Gerberding served as a member of CDC's National Center for Infectious Diseases' Board of Scientific Counselors, the CDC HIV Advisory Committee, and the Scientific Program Committee, National Conference on Human Retroviruses. She has also been a consultant to the NIH, the AMA, the CDC, OSHA, the National AIDS Commission, the Congressional Office of Technology Assessment, and the WHO.

Dr. Gerberding has contributed to the *Annals of Internal Medicine*, the *American Journal of Medicine*, and numerous internal medicine, infectious diseases, and epidemiology journals.

Networking Reception back by popular demand…

The Georgia Aquarium

The change from a formal, sit-down dinner to a more informal networking reception was extremely well received in 2006. Comments indicated that the more informal reception encouraged attendees to interact with more of their colleagues and opened up more networking opportunities. This year, In addition to enjoying great food and a host bar, DIA guests will have exclusive access to the world's largest aquarium.

When?

The Networking Reception will take place from 7:00 to 9:00 pm on Sunday, June 17th, at the Georgia Aquarium.

Ocean Voyager

Where?

The Georgia Aquarium is located in downtown Atlanta across from Centennial Olympic Park, in very close proximity to the Convention Center.

What is there to do at the Georgia Aquarium?

With more than eight million gallons of fresh and marine water, 100,000 animals representing 500 species from around the globe and more than 505,000 square feet of total space, you're sure to see things you've never seen before! The Georgia Aquarium promises wonder and excitement around every corner.

Ocean Voyager

As you enter the huge atrium inside the building, you will be led into the facility by "a wall of fish" guiding you inside. You then can enter one of five galleries: Georgia Explorer has a light house; River Scout displays a cascading waterfall; Cold Water Quest has an ice covered cliff; Ocean Voyager offers a peek window into the huge habitat; and Tropical Diver has two video screens displaying the perspective of a fish on a reef. There are 60 habitats at the Georgia Aquarium with 12,000 square feet of viewing windows. The largest habitat holds 6.2 million gallons of water and measures 263' long x 126' wide x 33' deep, at its largest points. It was specially designed to house whale sharks alongside tens of thousands of other animals that typically live along a coral reef and in the open ocean. The Georgia Aquarium boasts a 100-foot long tunnel and one of the largest aquarium windows in the world with views into whale shark habitat. The second largest habitat, 800,000 gallons, was specially designed to simulate the natural habitat of beluga whales.



Cold Water Quest

Tropical Diver

What does it cost?

The cost of the Networking Reception is $70.00*, which includes:

- Shuttle transportation to/from the Convention Center, although the aquarium is a short walk through Centennial Park.
- Exclusive access to Georgia Aquarium! The aquarium is usually occupied by several thousand guests throughout the day.
- First-class food and beverages provided by Wolfgang Puck Catering, including Southern Flair, Pan-Asian, pasta and dessert stations. Complimentary soft drinks, wine, and beer will also be included.
- UNLIMITED NETWORKING OPPORTUNITIES*!*

Ocean Voyager

**Please indicate that you'll be attending this reception on your meeting registration form.*

Space is limited. Onsite registration cannot be guaranteed. Registration for Networking Reception only is not available. You must be registered for the meeting as an attendee, speaker, or exhibitor to register for the Networking Reception.

The DIA Experience – Connecting You to the Industry's Best and Brightest

Meet the Attendees Who Have Benefited from the DIA Annual Meeting Since 1964!

The DIA Annual Meeting is the event of the year for the pharmaceutical and related industries – and this year is no exception. With more than 1,000 speakers from the FDA, EMEA, and other regulatory agencies, 27 content-area tracks, and nearly 400 sessions, the 43rd Annual Meeting is geared to attendees of all professional, degree, and functional responsibility levels.

The results are in … **the 2006 DIA Annual Meeting attracted:**

- **over 8,500 attendees**
- **1,114 speakers**
- **768 exhibiting companies**

Be Sure to Opt in to DIA Membership!

Membership benefits include:

- Discounted Registration Fees
- Members Only Website
- Free Publications
- Access to the DIA Job Bank

✓ To join DIA, check the **I do** box under Nonmember Fee on your Annual Meeting registration form.

Professional Category



"The networking opportunities have opened up new doors, both personally and professionally."

Partner, Health & Life Sciences Group, Accenture

"An educational event I look forward to every year."

Executive Director, Global Regulatory Affairs, Amgen, Inc.

Degrees Held



Level of Responsibility



"The most well-resourced and well-organized event I have ever attended."

Vice President, International Regulatory Affairs, Wyeth Pharmaceuticals

Meeting Highlights

New this Year!

MULTITRACK PLENARY

Tuesday, June 19, 2007
8:00am-9:30am

Session Co-chairpersons

Stanley A. Edlavitch, PhD, MA
University of Missouri-Kansas City

Melvyn Greberman, MD, MS, MPH
Public Health Resources, LLC

- **Academic Health Centers**
- **Clinical Research and Development**
- **Clinical Safety and Pharmacovigilance**
- **Public Policy/Law**
- **Regulatory Affairs**

Drug Safety Reform: Actions and Implications

In response to growing concerns about health risks associated with approved drugs, the Food and Drug Administration asked the Institute of Medicine to assess and recommend improvements in the US drug safety system. The IOM committee focused its attention on drug review, safety surveillance, and related activities of the FDA Center for Drug Evaluation and Research. In addition, it considered the roles of the pharmaceutical industry, academia, Congress, and healthcare providers and consumers in improving the system. The panel will discuss the IOM recommendations, as well as actions of the FDA, Congress, PhRMA, and other key players, and their implications. The discussion will include an update on the current status of the Prescription Drug User Fee Act and other legislative initiatives.

Getting to Atlanta

Nation's "Best" Airport: The mission of Hartsfield-Jackson Airport is to be the world's best airport by exceeding customer expectations. We know many of our attendees will be flying into town and Atlanta has an airport that is second to none when it comes to flight transportation. Atlanta's airport is just 15 minutes from downtown Atlanta and the Georgia World Congress Center. Here are some other reasons Hartsfield-Jackson Airport makes Atlanta a great convention city:

- Over 80 percent of the US population is within a two-hour flight of Atlanta
- The airport is served by 2,400 flights to 250 destinations … every day
- Taxi and shuttle service make downtown a short 10-minute ride away
- MARTA (Metro Atlanta Rapid Transportation Authority) provides train service from baggage claim straight to downtown Atlanta and the Georgia World Congress Center
- Airport recognized as "The Best in Overall Passenger Satisfaction" (ATA Survey, 2002)

AirTran Airways is offering discounted air travel and unique benefits for DIA meeting attendees. These benefits include the following:

- A 10% discount on the lowest available AirTran Airways one-way fare
- No minimum stay length or Saturday night requirement
- Advance seat assignments at time of booking
- Confirmed upgrade to Business Class, when available, for passengers booking in the "B" and "Y" fare levels
- A *one-time waiver* of Change Fee per reservation for any name or itinerary change
- Attendees have the option of contacting the EventSavers Desk directly or they may book their reservations through their designated travel agency
- Travel Agents must book all EventSavers reservations directly with the EventSavers Desk to receive the 10% discount. Reservations booked through a travel agent General Data System or the Internet *will not* qualify for the 10% discount
- Attendees may travel three (3) days prior to the event start date and three (3) days after the event close date if they wish to spend any additional time at the event location

To take advantage of this special program, contact the AirTran Airways EventSavers Desk at 1-866-68EVENT (1-866-683-8368) for reservations. Please provide the Event Savers Coordinator with Event Code: ATL061707 and start saving today!

United Airlines & US Airways

Save through Area Pricing and Discount Fees

To obtain schedule information and the best fares, call United Airlines' Specialized Meeting Reservations Center at 1-800-521-4041.

Make sure you refer to Meeting ID Number 577AH.

This special offer applies to travel on domestic segments of all United Airlines, United Express, TED, and United code share flights (UA, operated by US Airways, US Airways Express and Air Canada).

Continuing Education

Select tutorials and sessions will offer category 1 credits, pharmacy contact hours, nursing contact hours, and project management PDUs. Credit for tutorials will be clearly identified in the preliminary program mailing in mid-March and credit for sessions will be indicated in the final on-site program.

Accreditation and Credit Designation The Drug Information Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for *AMA PRA Category 1 Credit(s)*™.

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants may earn up to 29.25 contact hours or 2.925 continuing education units (CEUs) for participating in the tutorials and annual meeting sessions.

The Drug Information Association (DIA) has been reviewed and approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1620 I Street, NW, Suite 615, Washington, DC 20006. The DIA has awarded up to 2.9 continuing education units (CEUs) to participants who successfully complete the tutorials and annual meeting sessions.

NURSING The Drug Information Association will offer nursing credits for various tutorials and annual meeting sessions in collaboration with Corexcel. Corexcel is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

PMI The Drug Information Association has been reviewed and approved as a provider of project management training by the Project Management Institute (PMI).

Call for Abstracts for the Student and Professional Poster Sessions

Poster Session Chairpersons

Francis B. Palumbo, PhD, JD
University of Maryland, School of Pharmacy

Françoise G. Pradel, PhD
University of Maryland, School of Pharmacy

Stephen A. Sonstein, PhD, MS
Eastern Michigan University

During its 43rd Annual Meeting, the DIA will hold two poster sessions. These sessions are excellent opportunities for attendees to present their research results to a diverse audience of clinical research professionals. All abstracts are peer-reviewed and selected based upon criteria listed below.

On **Monday, June 18,** the Student Poster session will take place. On **Tuesday, June 19,** the Professional Poster Session will occur. Eligible students must be defined as being full-time by their educational institution. Medical residents or fellows and post-doctorals are considered students. All other abstracts should be submitted to the Professional Poster Session.

STUDENT POSTER SESSION

Student Poster Session Awards
A total of $4500 in prize money will be awarded to student winners based on the following criteria:

- Bona fide research project
- Specific objectives and hypothesis
- Analysis of actual data and results
- Clear methods
- Conclusions

A maximum of 20 abstracts will be selected for the student poster presentations to be held on **Monday, June 18, 2007.** One listed author for each selected abstract will receive complimentary meeting registration, hotel room, travel expenses and a per diem allowance. Selected student poster presentations will be published in the *DIA Journal.*

PROFESSIONAL POSTER SESSION

A maximum of 40 abstracts from full-time professionals will be selected for the professional poster presentations to be held on **Tuesday, June 19, 2007**. Selected professional poster presenters will be required to pay the applicable meeting registration fee and will be responsible for all other expenses.

More detailed information will be provided upon acceptance.

All Poster Abstracts are due by FEBRUARY 15, 2007.

All abstracts should pertain to the interest areas represented by the Tracks within the Annual Meeting which are listed below:

GENERAL SUBMISSION REQUIREMENTS

Please read the following instructions carefully. Abstracts submitted incorrectly will be returned to the author.

1. All abstracts must be received through the DIA website by **February 15, 2007.**
2. A student may submit only one abstract.
3. Abstracts may not refer to specific brand names.
4. Abstracts should follow a structured format including ALL of the following categories: objectives, methods, results and conclusions. Each category is limited to 300 characters.
5. Abstracts will be reviewed and authors will be notified of results by **March 16, 2007.**
6. If an abstract is accepted, one author or the author's designee must attend the conference to present the abstract in order to have it listed in the conference program.

Poster boards are four feet high and eight feet wide (4' x 8').

- Academic Health Centers
- Advertising
- Biotechnology
- Chemistry, Manufacturing and Controls/ Good Manufacturing Practices
- Clinical Data Management
- Clinical Research and Development
- Clinical Safety and Pharmacovigilance
- Clinical Trial Management/Clinical Supplies
- Electronic Regulatory Submissions/ Document Management
- eClinical
- Good Clinical Practices
- Impact of Medical Products and Therapies
- Information Technology
- Investigator Sites
- Marketing and Sales
- Medical Communications
- Medical/Scientific Writing
- Natural Health Products
- Nonclinical Laboratory Safety Assessment
- Outsourcing
- Project Management/Finance
- Public Policy/Law
- Regulatory Affairs
- R&D Strategy
- Statistics
- Training
- Validation

All abstracts should be submitted online. The deadline for submitting online poster abstracts is **February 15, 2007**. To submit an abstract for the Student or Professional Poster Session at DIA's 2007 Annual Meeting, please visit the DIA website – **http://www.diahome.org**. Click on **Get Involved** at the top right of the screen and **Submit Abstract** on the left navigation bar and follow the instructions.

Questions? Contact **Joanne.Wallace@diahome.org** • Tel +1-215-442-6180

Preliminary Session Topics

Following are the session topics that have been scheduled as of December 12, 2006. Updated information will be included in the preliminary program which will mail in mid-March.

Please monitor www.diahome.org for program updates and online registration.

AD – Advertising

Enforcement Update from FDA

How Fraud and Abuse Cases are Changing the Corporate Landscape

Direct-to-consumer Update from the FDA

Direct-to-consumer Update from Industry

A Primer on Advertising Regulation

FDA, Fair Balance, and False Claims: Can Companies Distribute New Data and Support CME?

Redefining the Roles of Medical Science Liaisons and Sales Representatives: Separating Science from Marketing

AHC – Academic Health Centers

Multitrack Plenary Session **(AHC, CP, CR, PP, RA)**
Drug Safety Reform: Actions and Implications

Integrating Research and Clinical Care in Academic Health Centers

Global Challenges with Bioethics in IRB's Training

Producing Epidemiologic Data in Latin America through Registries: Collaboration between Academia and the Pharmaceutical Industry

Education in Clinical Research/Opportunities in India

Clinical Trials from the Sponsor Viewpoint: Is It a Sprint or a Marathon?

BT – Biotechnology

Progress in Systems Biology: Advances in Knowledge-based Drug Development

Process Validation during Clinical Development of Biological Medicinal Products

Research and Development of Response Prediction Molecular Markers and their Integration into Clinical Drug Development in Oncology

Nonclinical Models for Biotechnology Products Used for Acute Radiation Syndrome

Phase 0/Phase 1: Successful Transition to Clinical Supplies

The "OMICS" Initiative: Leveraging Genomics, Proteomics, and Metabolomics for Diagnostics Development

Transitioning from Stem Cell Research to Commercial Applications

Hot Topics in Biotechnology

Gene Therapy

Biosimilars

CDM – Clinical Data Management

Case Studies on Time Critical Data Access Using Phase I EDC Programs

Meeting the Challenges for Data Monitoring Committees

Data Warehousing Concepts for SDTM-compliant Information

Convergence of Healthcare and Life Sciences: Enhancing the Value Chain

Good Registry Practice: Standards, Design, Use, and Valuation of Patient Registries and Methods and Best Practices

Implementing a Comprehensive Lab Data Management Strategy

The Path to the Future: eCDM or No CDM

Overall Data Integrity Plans for Working with Data from Multiple Vendors

Virtual Data Management Models

Clinical Data Management Considerations for Oncology Trials

Outsourcing in Data Management: Thinking Global, but Still Acting Local?

EHR Considerations for Clinical Data Management

CMC/GMP – Chemistry, Manufacturing, and Controls/ Good Manufacturing Practices

Update on FDA Initiatives for Postapproval CMC Changes

Implementing CMC Quality-by-design (QbD) Strategies for Emerging Companies

CMC Regulatory Agreement

Lessons Learned from CMC Pilot Program: An FDA Perspective

Implementation of QbD for Biotechnological Products

Update on FDA cGMP Initiatives and Guidances

Lessons Learned from CMC Pilot Program: An Industry Perspective

Role of Multivariate Analysis in QbD Pharmaceutical Development

Challenges in Implementing ICH Q8 & Q9 Guidelines in Global Submission

Updates on ICH Q8 (R) and Q10 Guidelines

CP – Clinical Safety and Pharmacovigilance

Multitrack Plenary Session **(AHC, CP, CR, PP, RA)**
Drug Safety Reform: Actions and Implications

Adverse Event and Medication Error Coding: Is MedDRA® Up to the Task?

Approaches to Quantifying Benefit-risk Assessments: Going Beyond Intuition

Can Risk Communication Be Improved? Pitfalls and Progress

CP – Clinical Safety and Pharmacovigilance *continued*

Clinical Safety Risk Management in Preapproval Drug Development

Data Mining in Pharmacovigilance: Misconceptions and Misunderstanding in Data Mining and Signal Detection

Detecting Safety Signals in Clinical Trials

FDA's Quarterly AERS Data Extracts: Availability and Use for Signaling

Global Electronic ADR Exchange: Where Are We Now and What Is Next?

Global Individual Case Safety Reports (ICSRs): Can Quality Data and Processing Efficiency Go Hand in Hand?

Implementation of Risk Management Plans in Japan

MedDRA® as a Pharmacovigilance Tool: Data Retrieval and Standard MedDRA® Queries (SMQs)

Postmarketing Safety Studies and Intensive Event Monitoring Techniques: What Have We Learned?

Regulatory Inspections of Industry Pharmacovigilance Operations

Risk Management for Vaccine Products

Selection and Performance of Safety Database Systems

Streamlining Adverse Event Case Management

Use of Disease and Other Registries: Lessons Learned for Use in Risk Management

CR – Clinical Research and Development

Multitrack Plenary Session **(AHC, CP, CR, PP, RA)**
Drug Safety Reform: Actions and Implications

A Case Study: Challenges and Suggestions on Patient Recruitment and Retention

Actuarial Methods within Pharmacoeconomics and Clinical Trials

Adaptive Trials Case Study in eClinical

Applying Lean and Six Sigma to Eliminate Waste and Streamline Planning and Execution of Clinical Trials

Are Site Monitoring and Data Management a Waste of Time?

Arsenic and Old Lace: How to Avoid a Comedy of Errors when a Thorough QT/QTc Study Cannot Be Performed

Assessing the Impact of Increasing Protocol Complexity on Study Conduct Performance

Biomarker Validation and Qualification for Regulatory Decision Making

Clinical R&D Outsourcing to India: What Do You Outsource to Whom?

Clinical Research and Drug Registrations in Developing Countries (BRIC – Brazil, Russia, India and China)

Common Issues and Solutions for Thorough QT ECG Trial Design

Cost Containment in Clinical Research: What Is Being Done?

Crohn's Disease and Ulcerative Colitis: FDA and EMEA Perspectives

Different Approaches: The Use of Key Enrollment Optimization Processes, Clinical Investigative Networks and eClinical Processes to Impact Clinical Trial Efficiency

Enhancing Patient Compliance in Clinical Trials with eTechnology

Ethnic Outreach and Inclusion in Clinical Trials and its Impact on the R&D Business, Regulatory and Clinical Development Process in the Pharmaceutical Industry

CR – Clinical Research and Development *continued*

Examining Investigator Meetings Best Practices

Factors Influencing the Speed of Clinical Trial Study Completion

Global Development of Cardiovascular Drugs

Global Development of Vaccines

How to Work with Your IRB

Human Phase 0 Microdose Studies: What Will They Deliver?

Improving Success of Psychopharmacological Clinical Trials: A Path to Failure

Managing the Placebo Response in Psychiatric Clinical Trials

Oversight of Research: Data Safety Monitoring Committees (DSMC) – A Systems Approach

Patient Recruitment: Strategic Approaches to Optimize Outcomes

Pediatric Exclusivity Trials: Lessons Learned from the Field

Personalized Medicine and Personalized Drug Development: Case Studies and Progress to Date – Parts 1 and 2

Prevention of Fraud and Noncompliance in Clinical Research: What Was and Is Being Done?

Regulatory Requirements in Late Phase Studies: Do We Really Know What They Are?

Successful Phase I Clinical Trials

Targeted Site Start-up Support Strategy in Clinical Research

The Business Case for CDISC Standards: Implementation Approaches and Metrics

The Country Study Manager Survey: 2006 Research Data Makes the Case for a New Approach

Update to Radical Change in Clinical Development

Using Adaptive Design and Enrichment Designs to Speed Oncology Drug Development

CTM/CS – Clinical Trial Management/ Clinical Supplies

The Implementation of a CTMS System and Its Impact

Multinational Clinical Trials in China

Clinical Trials in Asia Pacific: Advantages and Challenges

Understanding Clinical Trial Volunteer Experiences and Examining Financial Changes

The Great Debate: Can Site Performance Be Predicted?

New Techniques for Maximizing Enrollment at Academic Health Centers

Finding Top-performing Sites: A Considered Approach

A Simple Solution for Removing Clinical Supplies as a Rate-limiting Step for the Adaptive Trial Design

Becoming a Sponsor of Choice for Clinical Investigators

Research into the Use of Productive Metrics to Determine Clinical Performance

Identifying and Overcoming Site Initiation Delays in Multinational Clinical Trials

Recruitment of Minority Sites for Clinical Trials

Delivering Effective Feedback for Clinical Research Managers

Improving the Clinical Supply Chain Management Process

EC – eClinical

The Role of Electronic Data Capture in Adaptive Clinical Trials

NIH Roadmap Program and Development of Therapeutic Area Data Standards: Case Studies in TB and Cardiology

Crossing the BRIDG to the Future: Implementation Case Studies of the HL7/CDISC BRIDG Model

Using CDISC Standards and eClinical Technologies to Improve Patient Safety Monitoring during the Conduct of Clinical Trials

Global Adoption of eClinical Technologies

2012: eClinical Odyssey

The eClinical-eHealth Data Management Environment

ERS/DM – Electronic Regulatory Submissions/ Document Management

Document Management Repositories

FDA: eCTD Compliance – Parts 1 and 2

International eCTD

FDA Standards Initiatives

Lifecycle Management

eCTD Standards

FDA Electronic Submission Processing

Labeling (US)

eCTD Case Studies

Records Management

Document Management

Content Management

eCTD for Small Pharma

eIND

Product Information Management (PIM) in Europe

FI – Finance

Sustaining Pharmaceutical Development Pipelines

Finance Is from Mars, Clinical Development Is from Venus: The Financial Accruals and Forecasting Processes

GCP – Good Clinical Practices

Clinical, Logistical and Financial Considerations of Pediatric Research

Clinical Trial Registries and Results Databases: Are You Ready for the Audit?

How to Be Prepared for an FDA Audit

Good Clinical Practices (GCPs) and ISO 9000: A Winning Combination

Quality Risk Management in GCP: The Essentials

GCP – Good Clinical Practices *continued*

Working with and Managing Contract Auditors

GCP Town Meeting Session: Quality Systems and the QA Role in Small- and Medium-sized Companies

Virtual Realities: Quality Considerations when Using Outsource Providers

Successful Implementation of a Quality Management System

An Effective SOP Process that Really Works

Conducting Effective CAPA Following an Audit

The Uses of Technology to Improve Consent: What Are They and Are They Effective?

The Additional Challenges of Auditing an Investigational Site Using Electronic Data Capture (EDC)

IMP – Impact of Medical Products and Therapies

Using Electronic Medical Records for Clinical Research

Data Mining: Perils, Pitfalls and Pragmatism

Integrating the Reimbursement Strategy for a Combination Medical Device into the Clinical Trial Program

Linguistic Validation (aka Translations): The State of the Science

IS – Investigator Sites

When Sponsors Sue Sites: A Real-life Case History

Investigator Budgets and Reimbursement: The Impact on Patient Enrollment and Retention Objectives

IRB Site Visits and Audits

Feet on the Street: Using Community Outreach to Recruit Study Subjects

Hurricane Katrina: Lessons Learned One Year Later

Emergency Procedures for when a Sponsor Goes Bad

Recruitment and Retention Strategies and Solutions for Visible Minorities into Clinical Trials

IT – Information Technology

Leveraging Electronic Health Records in Clinical Research

Protecting Intellectual Property

Clinical Data Warehouse: Approaches and Pitfalls

GMP, GLP, GCP… Why Not GSP – Good Systems Practice?

The Move to Structured Content and XML: Patterns and Implications in Life Sciences

Issues and Case Studies in Safety Data Migration

Deploying Life Science IT Using IEEE Methods

Best Practices for Technology Implementation

IT – Information Technology *continued*

Standard Controlled Terminology: A Successful Partnership between CDISC and NCI Enterprise Vocabulary Services

Implementing Biological Sample Management and Biobanking Systems

Next Generation Application Integration Using Web Services

Utilizing Open Source Software in GCP-compliant Environments

The Future of Technology in Clinical Development and Life Sciences

Using Information Visualization to Link Decision-making across a Matrixed Organization

Semantic Web Technologies in Drug Development

Evolving Technologies for Interoperability

MA – Marketing and Sales

Maximizing ROI (Return on Information)

Lifestyle-based Analytics: A Revolutionary Marketing Approach

Defining the Value of Pharmaceuticals

MC – Medical Communications

Standardizing Information Sharing between Medical Information Professionals and Regional Medical Liaisons by Developing Tools to Ensure Compliance and Consistency

Medical Liaison Survey #3: Assessing Practice Trends across the Pharmaceutical Industry

Approach, Design and Development of Medical Science Liaison Portal

Elevating Scientific Expertise via Formal Assessments

Health Education: Teaching Consumers about the Safe Use of Medicines

Establishing Principles to Support Co-marketed Products between Two Medical Information Departments: One Company's Perspective

Sharing Medical Information Online: Weighing the Risks versus Benefits

MW – Medical/Scientific Writing

Providing Data Displays to Support Communication of Safety Information

The HL7/CDISC Glossary: Mapping the R&D Process with a Common Vocabulary

The Evolving Role of the Investigator Brochure in Global Submissions

CTD Summaries as Key Reviewer Tools

Submitting an IND in eCTD Format: Lessons Learned

Overview of Publication Writing: Maximizing Partnerships

The "Other Documents" that Medical Writers Impact

Writing for Patients

Efficient Authoring Using Contractors

Medical Writing for Risk Management and Pharmacovigilance

NC – Nonclinical Laboratory Safety Assessment

Adverse Effects of Anti-cancer Drugs: A Problem of the Past

Drug-induced Liver Toxicity

Nonclinical Development of Nanopharmaceuticals: How Much is Covered by Existing Guidance?

Safety Assessment of Biotechnology-derived Medical Products – Parts 1 and 2

Humanized Models

Changing Paradigm of Carcinogenicity Testing

Predictive Safety Testing Consortium

NHP – Natural Health Products

Validating Botanicals for the Management of Diabetes Mellitus

"Next Generation" Natural Health Products: Protecting Intellectual Property of Complex and Polymolecular Drugs

Phytomedicine Development in Latin America: Interphase between Science and Development

Asia Strategy on the Research, Development and Regulation for the Modernization of Herbal Medicine

Challenges and Solutions in the Evaluation of Traditional Chinese Medicine (TCM)

Characterizing Variability of Botanical Products: Impact on Scientific Research and Product Development

Impact of Quality and CMC on the Development and Use of Botanicals and Other Natural Health Products

International Initiatives for Natural Health Products

Global Regulation of Botanical Products

OS – Outsourcing

Lessons Learned: A Non-confrontational Technique to Improve Sponsor-provider Team Performance – Parts 1 and 2

A Case Study of a Successful Functional Service Provider (FSP) Relationship: Outsourcing Site Contracts

Benefits and Challenges of Implementing Standards in Outsourced Studies

Transforming Five New Clinical Development Strategies into Real Results – and What We Can Learn from the Industries that Have Done It

Improving CRO Negotiations to Accelerate Time to Market

Outsourcing Clinical Trial Logistics

India: An Emerging Clinical Research Destination – Challenges and Advantages

The State of Clinical Outsourcing: Results from Avoca's 2007 Industry Survey with a Focus on Change Orders – The Challenges, the Impact and the Effect on Relationships

Outsourcing Late-phase Studies: What to Do, What Not to Do and Why

OS – Outsourcing *continued*

Functional Service Providers and the Next Stage of Evolution for Clinical Data Management

Functional Outsourcing: Beyond Data Management

R&D Outsourcing in Japan: Successes and Challenges

Outsourcing Clinical Trials in China: Opportunities vs. Difficulties

PM – Project Management

Who Is This Jack-of-all-trades: The Pharmaceutical R&D Project Manager?

Evolving Operational Models in the Pharmaceutical Industry: Project Management Perspective

Applying Six Sigma Methodology

Getting Started with Portfolio Management

PMs as Project CEOs and the Effective Project Managers Tool Chest

Ending the Isolation of Project Management in Drug Development

Value of Project Management Function in Drug Development in Japan

The Evolving Role of Project Management in Drug Development

Integrated US/Japan Effective Team Management

The Methodology of Process Metrics in Leading an Organization to Success

The Playing Field of Project Management: A Dynamic Investigation of a Team and their Winning Strategy

Creating Dynamic Product Development Teams

Development of an Integrated Molecule and Nonmolecule Forecast

eStrategy: Preparing Product Launch Teams Using a War Game Simulation

Case Studies of Critical Chain Project Management in the Pharmaceutical Industry

Project Management as a University Research Tool

PP – Public Policy/Law

Multitrack Plenary Session **(AHC, CP, CR, PP, RA)**
Drug Safety Reform: Actions and Implications

Off-label Promotion and Physician Liability

Personalized Medicine: A Perspective Beyond Science

Personal Health Records in Pharmaceutical Development

Strategies for Maximizing the Financial Portfolio through Intellectual Property

New Paradigms of Drug Regulation

Product Liability

Clinical Trial Registration: Are Registries Useful and User Friendly?

Clinical Trials on Trial: Potential Legal Liability Arising from Clinical Trials

Civil and Criminal Liability from Clinical Trials: What Are the Legal Risks of Clinical Trials?

BPCA Report Card

Legal Remedies and Drug Approvals: During and after the Approval Process in the US and the EU

RA – Regulatory Affairs

Multitrack Plenary Session **(AHC, CP, CR, PP, RA)**
Drug Safety Reform: Actions and Implications

Added Therapeutic Value: How to Communicate It

Avoidable Pitfalls in Drug Development

Best Practices for Addressing Pharmaceutical Multilingual XML Requirements

Best Practices in Preparing for and Participating in a Pre-IND Meeting

Biosimilars in Europe

Challenges for Global Labeling: New FDA and European Requirements

4th Update: US-EU Agreement Regarding Exchange of Information among Regulators

Clinical Development of Oncology Drugs in Japan

Clinical Trial Disclosure: Getting Ready for the Regulations

CMC Challenges and Considerations for Clinical Trial and Marketing Applications in China

Combination Products – Parts 1 and 2

Compassionate Use Programs in the EU

Five-year Update on Regulatory Intelligence Utilization by Industry: 2002 to 2007 and Three Industry Examples of RegIntel Programs

Critical Path in Japanese Drug Development Strategy Using Foreign Data

Critical Path: Biomarker from Concept to Action

Development of Oncology Products in the EU and US: Can It Be Better and Faster?

Achieving a Global Trademark

Drug Development in Japan: Drug Development Models to Ensure Acceptance of Preclinical Data Requirements as Part of Global Drug Development

Effective Milestone Meetings with FDA

Fast Track! Accelerated Approval! Priority Review: Primer in Regulatory Paths to Approval

FDA Guidances: How to Make Comments Count

FDA's Drug Establishment Registration and Drug Product Listing System

Fixed-dose Combination Products: Registration Strategies and Case Studies

Global New Drug Development: Regulatory Challenges, Successes and Recommendations from a US-based Company

Good Review Management Practices (GRMPs)

Good Review Practices in the United States and Canada: A Comparison of Attempts to Standardize Product Review Practices among Regulatory Organizations

Highlights Data Elements (HLDEs): One Year's Experience with Computer-processable Highlights for US Prescribing Information

Imaging in Drug Development

RA – Regulatory Affairs *continued*

Implications of Patient-reported Outcomes Guidance on Electronically Collected (ePRO) Data

Maximizing the Benefits of Medicines Information through Readability Testing

Nanomedicine: The Way Forward

New Directions and Innovations in Canadian Drug Regulations: The Canadian Approach to Draw a Critical Path to Better Drug Regulations and Development

Optimizing EU Regulatory Strategy

Outlook for Changes in Japanese Regulatory and Clinical Development Environment

Partnership in Regulatory Harmonization: Revival of Pharmaceutical Evaluation Report (PER) Scheme in Asia

Pharmaceuticals in the Environment

Phase III: Are You Studying the Right Dose?

PMDA Challenges for Global Drug Development including Japan

Postmarketing Commitments: Operational Issues and Public Perceptions

Prescription Drug Labeling: FDA's New Regulation for the Content and Format of the USPI – One Year Later

Quality Submissions Begin with Quality Deliverables

Running Clinical Trials in Argentina and Mexico

Scientific Advice in the EU

Site Selection Risk Models for FDA Inspections and Theoretical Considerations

Strengthening the Infrastructure: Supporting Drug Safety Policy Development, Risk Communication and Healthcare Community Outreach

The Evolution of Risk Management Plans

US/EU Risk Management Initiatives

New Pediatric Legislations in the EU

Practical Implementation of EU Pediatric Legislations

RD – R&D Strategy

Mapping the Clinical Investigator Landscape

Experimenting with Clinical R&D Management Metrics Using the Latest Computer Technology

Drug Development Down the Road

Globalization of Industry-sponsored Clinical Trials: Evidence on Recent Trends

Emerging Trends in the Economics of New Drug Development

Japan Challenges to Global Simultaneous Drug Development: Adapting Japanese Environments to Worldwide Drug Development

Rainmaker for the Biopharmaceutical Industries in the Emerging Markets

Improvement in Japan's Clinical Trial Environment: A Sponsor Company Perspective

ST – Statistics

Graphical Analysis of Clinical Safety and Efficacy Data

Design and Analysis Issues in Analgesic Trials

Early Successes with Adaptive Designs

Statistical Analysis with Missing Data

Statistical Computing Environments: Part B – Setting Forth Requirements

Adaptive Methods in Phase II Proof-of-concept Trials in Practice

Open Source Statistical Software in Pharmaceutical Research and Development: Validation, Legal Issues, and Regulatory Requirements

CDISC and Statisticians: Implications and Implementations

Strategies for Ethnic Comparison in Global Cooperative Clinical Trials

Statistical Methodologies for Safety Assessments

Statistics in Drug Safety and Health Economics and Outcomes Research: Anything in Common?

TR – Training

Searching PubMed®: Trade Secrets from Three 4-Star Medical Library Scientists

Training Investigators and Study Coordinators: Alternatives/Supplements to Investigator Meetings

eClinical Meets eLearning: Theory to Practice to Best Practice

Rapid Development/Rapid Delivery of eLearning Solutions to External Clinical Trial Personnel

Self-guided Mentoring Program Administered by Training

Podcasting, Interactive Simulations and "On Demand" Web Assistants: Delivering Your Courses via the Latest Technologies

A Blended Learning Approach to Establishing a Global Standards and Practices Program for Clinical Study Documentation

Practical Models for Training Clinical Research Monitors

Effective Training of Study Site Staff for Better Clinical Trials

Networking as a Personal Disaster Preparation Plan: Helping You Stay Up when the Sizing is Down

Pre-hire Assessment and Mapped Training Curriculum to Speed On-boarding Process

Getting the Message Across: It's All about the Presentation

MedDRA® Training: A Mentor-protégé Approach

Bringing Global Staff to Headquarters for Training

VA – Validation

CSV Fundamentals

Extraordinary Opportunities: Issues with Regulated Computerized Systems and How to Meet Them

Validation Quality and Costs: It's All about Risk

Assessing and Auditing Clinical Computerized Systems

Red Apple II

Current Regulatory Issues: SOX and Beyond?

Measurement of Quality without the Pain

Confirmed Tutorials (as of January 8, 2007)

DIA's preconference tutorials, scheduled for June 16-17, 2007, are designed to broaden your knowledge in specialized subject areas related to the pharmaceutical industry. Medical, pharmacy, nursing, project management, and IACET continuing education units will be available for various tutorials. As of December 12, 2006, the following tutorials are being offered.

Continue to monitor www.diahome.org for tutorial updates and online registration. ***Space is limited so REGISTER EARLY!***

Half Day • Saturday, June 16, 2007
1:00 pm-4:30 pm — $375

#30 Getting Your Clinical Operations on the Right Track: Strategy, Knowledge, People, and Process
Laurie Halloran, MS, CCRA
President and Chief Executive Officer, Halloran Consulting Group

#31 Leadership: How to Organize and Lead People in Group Work
Mike Laddin, MS, MBA
President, LeaderPoint

#32 This tutorial was rescheduled as of January 8 to #87 on Sunday, June 17, 2007, 1:00 pm-4:30 pm. New Release of EU Regulatory Requirements: Pharmacovigilance in the Pre- and Postmarketing Phase and eReporting

#33 The Investigator's Brochure: Best Practices for Writing and Updating
Peggy M. Boe, RN
Director, Professional Services and Medical Writing, Image Solutions, Inc.

#34 Project Management for the Nonproject Manager
Martin D. Hynes, III, PhD, MS
Director of PR&D Operations, Eli Lilly and Company
Robert L. Judd
Director, Program Management, Kosan Biosciences, Inc.

#35 The Scientific and Economic Benefits of Flexible Adaptive Trial Methodology Designed to Achieve Early Registration and Robust Results: Raptiva and Fabrazyme® as Case Studies
P.K. Tandon, PhD
Vice President, BioMedical Operations, Genzyme Corporation
Marisa Bacchi
Director, Serono International

Full Day • Sunday, June 17, 2007
9:00 am-5:00 pm — $650

#40 Clinical Statistics for Nonstatisticians
Rafe Donahue, PhD
Research Associate Professor, Vanderbilt University Medical Center

#41 European Regulatory Requirements for the Conduct of Clinical Trials
Regina Freunscht
Head of Quality Assurance, Accovion, GmbH, Germany

#42 Pharmacokinetics and Pharmacodynamics: A Gentle Introduction
Michael J. Fossler, PharmD, PhD, FCP
Director, GlaxoSmithKline

#43 Principles of Safety Surveillance
Stanley B. Garbus, MD, MPH
Chief Medical Officer, Sentrx
Ralph E. Bobo, MD
Executive Vice President, Pharmacovigilance Practice, Medical Safety Officer, Sentrx

#44 Developing Realistic Drug Project Plans
Peter Harpum, MSc, MAPM
Director, Life Science Practice Leader, Harpum Consulting, UK
Randy Dunson, MBA, PMP
Principal of Equinox Consulting, LLC

#45 Excelling as a Supervisor or Manager in the Clinical Research Industry
Mary E. Briggs
Chief Training Officer, Focus Inc.

Half Day • Sunday, June 17, 2007
8:30 am-12:00 pm — $375

#50 Pharmacovigilance Audit
Steve Jolley
Vice President, Pharmacovigilance, Taratec Development Corporation
Doreen Lechner, PhD
Senior Vice President, Quality Assurance, Sentrx

#51 Fourteen Steps from Research to Development
Judi Weissinger, PhD
President and CEO, Weissinger Solutions, Inc.
Michael R. Hamrell, PhD
President, MORIAH Consultants

#52 Preparation of Integrated Clinical and Statistical Reports for Individual Studies
George D'Addamio, PhD
President, PharmaConsult, Inc.

#53 Japan Regulatory Environment: Overview of the Organization, Processes, Systems, and Changes Affecting Pharmaceutical Development
Robert Fike, MS, PhD
Assistant Vice President, Regulatory Affairs Japan, Wyeth Research Division of Wyeth

#54 A Compliance-driven Nonstatistical Risk Detection Process in Drug Safety
Pradip K. Paul, MBBS, MS
Head, CME Group, Global Pharmacovigilance and Epidemiology, sanofi-aventis Pharmaceuticals, Inc.

#55 Alcohol-Drug Interaction Studies: Understanding the Regulatory Requirements and Study Design Issues
Beatrice Setnik, PhD
Research Scientist, Ventana Clinical Research Corporation

#56 Market Access for Prescription Drugs and Biologics in Canada
Anne M. Tomalin, RAC
President, CanReg Inc., Canada

#57 eClinical: Optimizing the Clinical Trial Process
David P. Iberson-Hurst
Chief Executive Officer, Assero Limited, UK
Rebecca D. Kush, PhD
President, CDISC

Please indicate which tutorials you plan to attend and the total tutorial payment due on the registration form on the back cover.

#58 Producing Structured Product Labeling (SPL): XML and Data Elements
Kate Hamilton
Consultant, Alschuler Associates, LLC
FDA Representative Invited

#59 Best Practices Using MedDRA®
JoAnn Medbery, RN
Director, Dictionary Management Systems, Johnson & Johnson

Half Day • Sunday, June 17, 2007 1:00 pm-4:30 pm — $375

#70 FDA Enforcement: Understanding the Agency's Authority, How Violations Occur, How to Prevent Them, and How to Respond if Violations Do Occur
Michael A. Swit, Esq., JD
Vice President, Life Sciences, The Weinberg Group, Inc.

#71 Evaluation of Risk Management Programs Using Existing Databases
Annette Stemhagen, DrPh, FISPE
Vice President, Epidemiology and Risk Management, United BioSource Corporation

#72 Regulations, Guidance, Dockets, Specifications and MAPPs (Manual of Policies and Procedures): A Primer for Pharmaceutical Professionals
Representative Invited
Division of Biometrics III, CDER, FDA

#73 Analysis of Safety Data from Clinical Trials
Joachim Vollmar, MSc
International Clinical Development Consultants, LLC
Jürgen Kübler, PhD
Director, Global Head PRO, Novartis Pharma AG, Switzerland

#74 GCP, Clinical Trial Safety, and Pharmacovigilance Compliance: How Global Pharmaceutical Companies Can Cope in Interesting Times
Stephen A. Goldman, MD, FAPM, FAPA
Managing Member, Stephen A. Goldman Consulting Services, LLC; Adjunct Assistant Professor of Psychiatry, Uniformed Services University of the Health Sciences
Louise N. Lisansky, MS
President, LNL Clinical Research Consulting

#75 Planning and Conducting Clinical Trials in Oncology
Ronald Harning, PhD
Director of Clinical Research, Teijin America, Inc.

#76 The CRA Role for Compliance with Electronic Data Capture (EDC)
Teri Stokes, MS, MT (ASCP), PhD
Director, GXP International

#77 Collecting Abuse Liability Data during CNS Drug Development
Edward M. Sellers, MD, PhD, FRCPC
President and CEO, Ventana Clinical Research Corporation
Kerri Schoedel, PhD
Research Scientist, Ventana Clinical Research Corporation

#78 Development of Stem Cells Based Therapeutics, Including Human Embryonic Stem Cells, from Proof of Concept to Clinical Trials
Judi Weissinger, PhD
President and CEO, Weissinger Solutions, Inc.

#79 The Expanding Role of Clinical Site Monitors
Ken Light, MS
Solutions Partner, BusinessEdge Solutions, Inc.
Geoff Garabedian
Solutions Partner, BusinessEdge Solutions, Inc.

#80 Randomization and Trial Supply Management Using IVR: A Tutorial for Study Teams
Nikki Dowlman, PhD, DSc
Product Development Manager, ClinPhone Limited
Graham Nicholls
Product Development Manager, ClinPhone Limited

#81 Pharmacogenomics as a Tool to Accelerate Drug Development
William Lee
Regulatory Scientist, Cato Research
Michael P. Murphy, MSc
President and CEO, Gentris Corporation

#82 Introduction to Biomedical and Health Informatics
H. Dominic Covvey
Professor, NSERC/Agfa Research Chair in Health Informatics
Director, Waterloo Institute for Health Informatics Research, Canada
John H. Holmes, PhD
Assistant Professor of Medical Informatics in Epidemiology at HUP Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine

#83 Regulatory Affairs in the European Union: An Overview of Registration Procedures for Medicinal Products in the EU
Brenton James, FTOPRA
Consultant in Strategic Regulatory Affairs in the European Union

#84 Pediatric Clinical Trials
Barry Mangum, PharmD
Faculty Pediatrics, Duke Clinical Research Institute (DCRI)
Danny Benjamin, MD, PhD
Faculty Pediatrics, Duke Clinical Research Institute (DCRI)

#85 The Changing Landscape of Pharmaceutical Product Launches
Courtney Rowell, MS, MBA
Managed Care Executive, Myriad Genetic Laboratories, Inc.
William R. Hahn
Vice President, Marketing and Business Development, Shaw Science Partners, Inc.

#86 The CDISC Standard: Four Models Working in Harmony
David P. Iberson-Hurst
Chief Executive Officer, Assero Limited, UK
Frank T. Newby
Vice President, Education and Member Relations, CDISC

#87 This tutorial was rescheduled on January 8 from #32 on Saturday, June 16, 2007, 1:00-4:30pm. New Release of EU Regulatory Requirements: Pharmacovigilance in the Pre- and Postmarketing Phase and eReporting
Representative Invited
Pharmacovigilance and Postauthorization Safety and Efficacy, EMEA, EU
Gaby L. Danan, MD, PhD
Expert, Global Pharmacovigilance and Epidemiology, sanofi-aventis, France

Exhibiting Companies (as of December 12, 2006) *Exhibit space is still available.*

AAIPharma
Accovion
ACM-Pivotal Global Central Laboratory
ACRS
Acurian
Adobe Systems, Inc.
Advanced Biologics, LLC
Advanced Biomedical Research, Inc.
Advanced Clinical Services LLC
Advanced Clinical Software
Aerotek Scientific
Allphase Clinical Research
Almac Clinical Services
Almac Clinical Technologies
Amarex Clinical Research
American Medical Writers Association
AmeriTrial OTC Research
Amgen Inc.
Anapharm
APEX International Clinical Research Co., Ltd.
Applied Clinical Trials Magazine
Aptuit Inc.
ArisGlobal
ARS, Inc.
ARX (Algorithmic Research)
Asian Clinical Trials (Division of Suven Life Sciences Ltd)
Assist Technologies
Asuragen, Inc.
Atcor Medical, Inc.
Averion International Corp.
Axiom Real-Time Metrics
B & C Group
BARC
BASi (Bioanalytical Systems, Inc.)
BattelleCRO
Baxa Corporation
BBK Worldwide
Beacon Bioscience
Beardsworth
Benchmark Research
Bilcare, Inc.
BioCor
Bio-Imaging Technologies
Biomedical Systems
Biopharm Insight
BioResearch Monitors, Inc.
bioskin GmbH
BioStorage Technologies Inc.
Biovail Contract Research
California Clinical Trials
Camargo Pharmaceutical Services
The Cambridge Group, Ltd.
Campbell Alliance
Canadian Arthritis Network/Canadian Rheumatology Research Consortium
CanReg, Inc.
CANTOX Heath Sciences International
Cardinal Health
Cardiocore
CCA, Inc.
CDISC
CEDRA Corporation
Center for Drug Evaluation, Taiwan
Cerner Galt
Cetero Research
Charles River Laboratories Clinical Research Services – Northwest Kinetics
Chesapeake Research Review Inc.
Chiltern International, Inc.
Christiana Care Research Institute
Cincinnati Children's Research Foundation
CIRION Clinical Trial Services Inc.
City List Co., Inc.
ClinForce, LLC
Clinical Conductor Enterprises
Clinical DataFax Systems Inc.
Clinical Financial Services
The Clinical Resource Network
Clinical Trial Media
Clinimetrics
ClinPhone Inc.
Clinsys
CMIC Co., Ltd.
Coast IRB
Cognitive Drug Research
Community Research
Compass IRB
CompleWare® Corporation
Concepts Worldwide
Constella Group, LLC
Contract Pharma
Copernicus Group IRB
Covance Inc.
CRF Inc.
Criterium, Inc.
CRL.Medinet
CTMS, Inc.
Cu-Tech, LLC
Cytel Inc.
Data Systems Analysts
DataCeutics, Inc.
DATATRAK International
DaVita Clinical Research
Delta Pharma, Inc.
Dendrite Clinical Solutions
DGP Group Ltd.
Diabetes & Glandular Disease Research Associates
Drexel University Online
Drug Safety Alliance, Inc.
DSG, Inc.
Duke Clinical Research Institute
DZS Software Solutions, Inc.
ECRON
Elite Research Network, LLC
Encore Research Group, LLC
Encorium
Endogen
Endpoint Research
Engel Publishing Partners
entimo AG
ePharmaSolutions
EPS Co., Ltd.
eResearchTechnology, Inc.
Esoterix Clinical Trials Services, Inc.
Essential Group, Inc.
EtQ, Inc.
etrials Worldwide
Eurofins Medinet, Inc.
European Medicines Agency (EMEA)
Eurotrials Scientific Consultants
Examination Management Services, Inc.
Excel PharmaStudies, Inc.
Fast Track Systems
FDA/CDER
FDAnews
Ferraris Respiratory
First Consulting Group
Fisher Clinical Services
FOI Services, Inc.
Forest Laboratories, Inc.
Formedix Ltd.
Future Science Group
GB Pharma Services & Consulting s.r.l
Gentiae Clinical Research
Gentris Corporation
Geny Research Group, Inc.
Genzyme
Global Languages & Cultures, Inc.
Global Lifescience Solutions, LLC
Green Mountain Logic, Inc.
GroupNet
Harrison Clinical Research
Hawaii Clinical Research Center
Health Decisions
Healthcare Communications Group
Howard M. Proskin & Associates, Inc.
i3 Research
IBT Reference Laboratory
ICON Clinical Research
iGATE Clinical Research International
Image Solutions, Inc.
IMIC - Mexican Institute of Clinical Research
Impact Clinical Trials
Imperial Clinical Research Services, Inc.
IMRO TRAMARKO
INC Research
Inclinix
Institute of Clinical Research India
Integrated Clinical Systems, Inc.
IntegReview Ethical Review Board
Integrium - Integrex
International Dermatology Research
IntraLinks, Inc.
invivodata
IRL (Pvt) Ltd
J&S Studies, Inc.

Johnson & Johnson Family of Companies
Joule Clinical Staffing Solutions
Kendle
Kforce Clinical Research Staffing
Klein Management Systems
LabConnect, LLC
Laboratorio Hidalgo
Logos Technologies Ltd.
LORENZ Life Sciences Group
Los Angeles Biomedical Research Institute
Lovelace Scientific Resources
LSUHSC-Shreveport
Maaguzi, LLC
MAJARO InfoSystems
Mayo Clinical Trial Services
McElroy Translation Company
McGuire Research Institute, Inc.
MedDRA® MSSO
MedFocus, LLC
Medical Graphics
The Medical Letter
MediciGroup® Inc.
Medidata Solutions
Medifacts International
MedNet Solutions
Medpace, Inc.
MedSource
MEDTOX Laboratories
MedTrials, Inc.
Merck Research Laboratories
META Solutions, Inc.
MIC Medical Corp.
Microsoft Corporation
Microsystems
Mid*Lands IRB
Monitorforhire.com
Mortara Instrument, Inc.
MSOURCE Medical Development
National Center for Health Statistics
Neeman Medical International
New England Research Institutes
New Orleans Center for Clinical Research
Next Generation Clinical Research
Northrop Grumman
Novotech
OCASA Logistics Solutions
Octagon Research Solutions
Omnicare Clinical Research
OmniComm Systems, Inc.
On Assignment Clinical Research
Open Text Corporation
Organon USA
Outcome
Pacific Biometrics, Inc.
Paragon Biomedical, Inc.
PAREXEL International
Patheon Inc.
Patient Interaction (Pi)
The Patient Recruiting Agency
PDP Courier Services Ltd
Penn Pharmaceutical Services Ltd.
Perceptive Connection, LLC
Perceptive Informatics, Inc.
Pharmaceutical C-Trials, Inc.
Pharmaceutical Executive Magazine
Pharmaceutical Institute
PharmaLinkFHI
PharmaNet
PharmaSys, Inc.
PharmaVOICE
Pharm-Olam International
Pharsight Corporation
Phase Forward
Phoenix Software International
PHT Corporation
PII
Pinnacle Trials, Inc.
Placemart Personnel Service
PleaseTech Ltd.
PPD, Inc.
PRA International
Premier Research Group plc
PRL Central Laboratory Services
Prologue Research
PROSAR
ProTrials Research, Inc.
PSI Pharma Support Intl.
Quality & Compliance Consulting, Inc.
Quality Associates, Inc.
Queensland Clinical Trials Network
Quest Diagnostics
Quintiles
QUMAS
Radiant Research
RadPharm
RCRC IRB
RCT – Global
Recruitech International
Regional Clinical Research
REGISTRAT, Inc.
Relsys International, Inc.
Research Across America
Research Solutions, LLC
Research Testing Laboratories Inc
ResearchPoint Inc.
Respironics
Rho, Inc.
Roche
RPS, Inc.
RWD Technologies, Inc.
Rx Trials Inc.
sanofi-aventis
SAS Institute
Satyam Computer Services
Schulman Associates Institutional Review Board, Inc.
SCRIP
Sentrx
SGS Life Science Services
Smith Hanley Consulting Group LLC
SNBL Clinical Pharmacology Center
SNOMED International
Source4
Spacelabs Medical Data
Sparta Systems, Inc.
Spectra Clinical Research
SRG Woolf Group, Inc.
St. Joseph Hospital
Statistical Solutions
STATKING Consulting, Inc.
Stiris Research Inc.
Strata
SYMFO
Synarc, Inc.
Synteract Inc
Tandem Labs
Taratec
Target Health Inc.
TGen Drug Development Services
Therapak Corporation
ThesIS (Thesaurus Information and Strategies, Inc.)
Thomson Healthcare
Thomson Scientific
TKL Research, Inc.
TNT Express
Total Root Concepts, Inc.
TranSenda
TransPerfect
Trial Management Group Inc.
Trident Clinical Research Pty Ltd.
Triligent International
Trio Clinical Research, LLC
TTC, LLC
UK Clinical Research Organization
United BioSource Corporation
University Clinical Research DeLand
University of California San Diego
University of Florida Center for Clinical Trials Research
University of Rochester Medical Center
Uppsala Monitoring Centre
Velos Inc
Veritas Medicine
VIASYS Healthcare
Virtify, Inc.
VirtualScopics Inc.
Vitalograph Ltd.
Volt Life Sciences
Waban Software
WebbWrites, LLC
Wiley Pharmafile
Wolters Kluwer Health
Woodley Equipment Company Ltd.
Working Words Inc.
World Courier Inc.
WorldCare Clinical Inc
Xceleron Inc
XERIMIS Inc.

Hotel Reservation Instructions

The Atlanta Housing Bureau will open for reservations on JANUARY 15, 2007.

The Atlanta Housing Bureau is coordinating all reservations, and arrangements for housing must be made through this housing bureau and not with the hotel directly. All housing reservation forms must be received by **May 15, 2007. DIA DOES NOT PROCESS HOTEL RESERVATIONS.** Attendees can make hotel reservations by any of the following methods:

ONLINE RESERVATIONS Log on to **www.diahome.org,** double click the Annual Meeting icon, and go to Housing Bureau Reservations, now open. *Please have your credit card, arrival and departure information ready.*

BY FAX **506-433-3033 (domestic and international)**

Please print or type all information to ensure accuracy. Complete each part below in detail for correct and rapid processing. For multiple rooms, this form may be duplicated. Confirmations will be sent to the individual listed below, **by email if provided.**

BY PHONE **866-413-5150 (domestic) / 506-637-0311 (international)**

Please have all of the information that is requested on this form ready along with a credit card number and expiration date for the $150.00+ room deposit.

BY MAIL Fill out this form completely and mail to **DIA/Atlanta Housing Bureau**, 233 Peachtree Street NE, Suite 100, Atlanta, Georgia 30303, USA

MAKING RESERVATIONS Please have the following information available if reserving by phone: • Name of convention: DIA Annual Meeting • 1st, 2nd and 3rd choice of hotel • Arrival/departure dates • Number of rooms requested • Type of room (single/double, etc.) • Number of persons in party • Arrival time • Credit card type, account number and expiration date • Names of all occupants of room • Daytime telephone number • Fax number • eMail address to which confirmation will be sent

DEPOSIT All hotels require a room deposit, **plus 15% tax**, of **$150.00** for a standard room, **$300.00** for a one-bedroom suite, and **$450.00** for a two-bedroom suite. The deposit amount is payable by credit card, or by check in US dollars, drawn on a US bank (by mail only). ***No wire transfers or purchase orders will be accepted.*** **No reservation will be processed without a deposit.**

CREDIT CARD Your credit card will be used as a guarantee but will not be charged immediately. The hotel may charge the deposit to your credit card after **May 15, 2007** when they receive the reservations for processing. Most major credit cards (VISA, MasterCard, American Express, Discover, Diners) are accepted. Each hotel will honor the Housing Bureau acknowledgement.

CHECKS Your deposit check must be made payable to **DIA/Atlanta Housing Bureau** in US funds drawn on a US bank and mailed to DIA/Atlanta Housing Bureau, at the address above. **No checks will be accepted after May 15, 2007.**

CHANGES/CANCELLATIONS/REFUNDS **Up until May 15, 2007,** all changes and cancellations should be made directly with the DIA/Atlanta Housing Bureau via phone, fax, mail, or email to **housing@atlanta.net. Data will be transferred to the hotels between May 16 and May 25 and changes/cancellations/reservations will NOT be accepted during this time. Beginning May 25, 2007,** changes and cancellations should be made directly with the confirming hotel. Cancellation policy is as follows:

Cancellations made on May 7, 2007, or earlier, will receive a full refund. If deposit was paid by check, a $25.00 processing fee will be deducted.

Cancellations made after May 7, 2007, will forfeit the full $150+ deposit.

Also, should a guest not arrive by their scheduled arrival date, the full reservation will be cancelled by the hotel and the $150+ deposit will be forfeited.

Please complete the following information and submit to DIA/Atlanta Housing Bureau by May 15, 2007.

First Name (please print) _____ Last Name _____ Middle Initial _____

Company/Institution _____

Address _____ City _____ State _____ Zip/Postal Code _____ Country _____

Tel _____ Fax _____ email _____

HOTEL INFORMATION Choice of hotel will be honored based on availability. If your choices are not available, we will select another hotel based on (check one):

☐ lowest rate ☐ distance to the meeting (prefer to be closer to the event)

HOTEL SELECTION Please list in order of preference.

1. _____ Arrival Date _____ Departure Date _____
2. _____ ☐ Smoking* ☐ Nonsmoking* ☐ 1 Bed* ☐ 2 Beds*
3. _____ ☐ Single ☐ Double ☐ Triple ☐ Quad

*This is a request only.

SPECIAL NEEDS *(attach a note if you need more room)* _____

Sharing with the following person(s) 1. _____ 2. _____

3. _____ 4. _____

PAYMENT INFORMATION ☐ Visa ☐ MasterCard ☐ Discover ☐ AMEX ☐ Diners ☐ Other _____

Credit Card # _____ Expiration Date _____

Name on Card _____ Signature _____

Attendees should make hotel reservations early to guarantee rates and availability.

Hotel Locator Map

Reproduced with permission of the Atlanta Convention and Visitors Bureau | (404) 521-6600 | www.atlanta.net

Hotel rates include a nominal $5 fee to help defray venue costs.

#1 Atlanta Marriott Marquis	#2 Embassy Suites Hotel Atlanta Centennial Olympic Park	#3 Hilton Atlanta & Towers	#4 Hyatt Regency Atlanta	#5 Omni Hotel @ CNN	#6 Westin Peachtree Plaza
Address 265 Peachtree Center Avenue	**Address** 267 Marietta Street	**Address** 255 Courtland Street NE	**Address** 265 Peachtree Street, NE	**Address** 100 CNN Center	**Address** 210 Peachtree Street, NW
Room Rates $174 Single $184 Double $194 Triple $204 Quad	**Room Rates** $189 Single $189 Double	**Room Rates** $149 Single $149 Double	**Room Rates** $179 Single $179 Double	**Room Rates** $179 Single $179 Double $204 Triple $204 Quad	**Room Rates** $169 Single $189 Double $209 Triple $229 Quad
Distance to Convention Center 8 blocks	**Distance to Convention Center** Across the street from Convention Center	**Distance to Convention Center** 9 blocks	**Distance to Convention Center** 7 blocks	**Distance to Convention Center** Across the street from Convention Center	**Distance to Convention Center** 6 blocks
Shuttle Offered Yes	**Shuttle Offered** No	**Shuttle Offered** Yes	**Shuttle Offered** Yes	**Shuttle Offered** No	**Shuttle Offered** Yes

Optional Tours

These activities provide an opportunity to enjoy the Atlanta area. A registration form follows on page 23, or you can register online. Log on to www.diahome.org, click the Annual Meeting icon, click the Networking Opportunities tab at the top of the screen, and select Tours. The Atlanta Housing Bureau will open for reservations on JANUARY 15, 2007. All tours depart from and return to the Georgia World Congress Center and will take place rain or shine.

STONE MOUNTAIN PARK

Sunday, June 17, 2007 • 11:00 am-5:00 pm

$72.00 per person

Guests are in for a treat as they visit the "Eighth Wonder of the World" – Stone Mountain Park. Formed over 300 million years ago, the giant granite rock rises 1,683 feet above sea level and covers 583 acres. The largest bas-relief sculpture in the world, the Confederate Memorial Carving pays tribute to three Civil War heroes – Confederate President Jefferson Davis and Generals Robert E. Lee and Thomas J. "Stonewall" Jackson.

The rock's top attraction is The Summit Skyride. This high-speed Swiss cable car provides a stunning view of the Confederate Memorial Carving as it transports guests more than 825 feet above ground to the top of Stone Mountain.

Visit the Antebellum Plantation and Farmyard to enjoy scenes of life in the 1800s. At the Stone Mountain Museum at Memorial Hall guests see and hear the story behind Stone Mountain and view true-to-scale elements from the world's largest relief carving.

Visit the Crossroads area and transport yourself to a 1870s Southern town bustling with activity. Take an exciting amphibious sightseeing experience on land and in water. You'll find Duck tours entertaining and interactive, culminating with a big splash into Stone Mountain Lake.

A THIRST FOR ATLANTA

Sunday, June 17, 2007 • 1:00 pm-5:00 pm

$49.00 per person

The World of Coca-Cola is an experience unique to Atlanta that cannot be found anywhere else in the world. Catch the excitement through exhibits and unique architectural style. Pass under an enormous three-dimensional Coca-Cola globe suspended 18-feet above the entrance, and step into a spectacular three story, sky-lit atrium. Guests move at their own pace through an easy-to-follow series of fun and fascinating exhibit galleries.

Guests depart the World of Coke and take a short drive to the CNN Center to enjoy a guided tour of the world-famous news studio. The studio tour features a number of behind-the-scenes demonstrations where guests learn how CNN makes images, like weather maps appear behind anchors and correspondents. Guests then take a guided tour of the 21-acre Centennial Olympic Park. The park, developed for the 1996 Summer Olympic Games, is the largest new City Park created in the United States in 20 years.

NOBELISTS OF GEORGIA

Monday, June 18, 2007 • 1:00 pm-5:00 pm

$39.00 per person

Celebrate the lives and principles of two Georgians who, using different paths, pursued a common goal: freedom and justice for all people. Both winners of the Nobel Peace Prize, Reverend Martin Luther King, Jr. and former President Jimmy Carter are best described as peacemakers. These two Georgians answered an individual calling to lead and motivate others in promoting fundamental human and civil rights for people around the world.

First, guests visit the Martin Luther King, Jr. National Historic Site located in the historic "Sweet Auburn" neighborhood. This site includes King's birth home, the Ebenezer Baptist Church, and his gravesite. Guests can view in-depth exhibits of the civil rights movement and King's life and legacy along with poignant documentaries.

After viewing the park, guests enjoy a short ride to the graceful Jimmy Carter Library and Museum. The museum includes photographs and memorabilia from the Carter presidency (1976-1981). The Jimmy Carter Library chronicles the Nobel Peace Prize winner's White House years. Of particular interest are a replica of the Oval Office, Carter's Nobel Peace Prize, a video on Camp David and presidential gifts from world leaders and constituents.

WELCOME TO TARA

Monday, June 18, 2007 • 5:30 pm-10:00 pm
$82.00 per person

As guests step into the grounds of Stately Oaks Plantation located in Jonesboro, Georgia, they almost believe that it's 1863 and they are back in the days of Rhett and Scarlett. Stately Oaks has a history as expansive and magnificent as its rooms. The home, built in 1839 is the epitome of Southern history and hospitality. It served as the model for Tara, the home of the famous Scarlett O'Hara in *Gone with the Wind*. The plantation is a stunning example of the past. The home was moved to its present location from outside of Jonesboro and named for the large trees surrounding it. Previously, it had housed both Northern and Southern troops during the Civil War in 1864. Everything from the white columns to the rocking chairs on the porch represents Southern living in the nineteenth century.

Costumed docents give guests a full tour of the antebellum home allowing guests to step back two centuries to antebellum life. Guests tour the downstairs including the original log kitchen and the upstairs bedrooms. After the tour, guests shop Judy's Country Store which dates from 1894 for some southern gifts to bring home. After shopping, guests view the grounds including the blacksmith's cottage and are led into the authentic one-room school house for a delicious southern dinner buffet. While enjoying Peach Cobbler and coffee, guests are treated to stories of the south and Civil War by an entertaining storyteller.

FROM PAGE TO STAGE

Tuesday, June 19, 2007 • 9:30 am-1:30 pm
$53.00 per person



Guests visit the Atlanta of the past and present featuring an author and a dazzling theater. The tour begins with a narrated drive down Atlanta's most famous street – Peachtree Street. As guests approach the Fox Theater, the tour guide points out the interesting architecture of this magnificent building. The "fabulous" Fox Theatre is one of the most lavish performing arts venues in the country. Guests explore the mysterious interior of the Fox Theatre, one of the few remaining exotic movie palaces of the 1920s. Middle Eastern and Egyptian designs create a dreamlike spectacle of grandeur. In addition to exceptional architectural design, the Fox Theatre also houses the second largest theater organ in the world, a Moller organ affectionately known as "Mighty Mo," as well as its original period furniture collection.

Next is a visit to the treasured place that helped put Atlanta on the map. The story of Margaret Mitchell and her work is crucial to understanding the history and culture of the city she loved, and The Margaret Mitchell House and Museum stands as a testament to the past. From 1925 until 1932, Margaret Mitchell wrote her Pulitzer prize-winning novel, *Gone with the Wind* at her apartment in this home. Margaret Mitchell's apartment is the only interior space of the restored house that is preserved as an apartment with all furnishings of the period. Architectural features include the famous leaded glass window out of which Margaret looked while writing.

VISIT THE CDC

This tour will be offered on both Tuesday and Wednesday. Be sure to select the desired day on the registration form.

Tuesday, June 19, 2007 • 1:00 pm-4:00 pm
$39.00 per person

Wednesday, June 20, 2007 • 1:00 pm-4:00 pm
$39.00 per person

Please note: A government-issued ID is required for entry into the CDC. The CDC does not allow access to the laboratories or research areas of the campus.

Celebrating its 60th year in 2006, it was founded in 1946 to help control malaria and has remained at the forefront of public health efforts to prevent and control infectious and chronic diseases, injuries, workplace hazards, disabilities, and environmental health threats. Guests enjoy the exhibit area of the CDC.

The "Global Symphony" features three, three-minute stories that describe in depth CDC's contributions to the elimination of polio, the eradication of Legionnaire's disease, and the battle to stem the rise of obesity in the United States. The stories are complemented by a wide range of statistics on public health topics ranging from HIV/AIDS to worker safety.

The "Roots of CDC" traces the origins and early history of CDC through 1976. The story is told through documents, photographs and objects such as an early 20th century quarantine sign, the microscope of Dr. Joseph Mountin – the founder of CDC, early CDC bulletins, and an iron lung.

The featured traveling exhibit in June is "Deadly Medicine: Creating the Master Race". Created by the U.S. Holocaust Memorial Museum, this exhibition explores the history of Nazi eugenic programs during the Third Reich and features artifacts, photographs, video testimonies and film footage.

After guests tour the permanent and traveling exhibits with a CDC guide, they enjoy a private speaker on a topic to be determined who will provide more insight into the CDC. A question and answer session will complete the CDC tour.

BUCKHEAD HOMES AND HISTORY

Wednesday, June 20, 2007 • 9:30 am-1:30 pm
$47.00 per person

Buckhead has a reputation as Atlanta's most affluent and elegant district. But its name preserves the legacy of its frontier beginnings, when hunting in the virgin forests was the main local enterprise. Now Buckhead is the jewel of Atlanta, an area of gracious homes, elegant hotels, shopping centers and some of the cities best restaurants.

A drive along West Paces Ferry Road provides a view of the most exclusive homes in Atlanta. The first stop is Georgia's elegant Governor's Mansion, a stunning example of Classical Revival architecture. After a short drive, guests arrive at the Atlanta History Center which features a museum housing memorabilia from Atlanta's past. The exhibits are open for guests to experience the Civil War, Georgia's Native Americans, the legendary Atlanta golfer Bobby Jones, and the newest exhibit on the 1996 Centennial Olympic Games held in Atlanta.

After walking the beautiful grounds of the History Center, guests visit The Swan House, a former private home, built for Edward Inman and his wife in 1929. The Swan motif appears in every room of this 1920s masterpiece and the home sits on beautiful gardens.

In comparison, the Tullie Smith Farm, an Atlanta "plantation plain-style" farmhouse of the 1840s, has been completely restored and authentically furnished. It is an actual working farm one might have found around Atlanta before the Civil War complete with docents working the garden. Guests enjoy browsing among the several outbuildings, including a wonderful detached kitchen, a blacksmith shop and stables.



Photo Credit for CDC Building: James Gathany
All other photos courtesy of the Atlanta Convention and Visitors Bureau

Optional Tours Registration Form

Drug Information Association • Atlanta, Georgia • June 17-20, 2007

ALL TOURS ARE BASED ON A MINIMUM OF 35 GUESTS. Tours must meet this minimum guest requirement in order to run. In the event tours don't make this minimum, the tour will be cancelled and guests will receive a full refund. The registration deadline is Monday, May 14, 2007. All requests for refunds must be received prior to this date. No refunds will be accepted after this date.

Please **RETURN THIS FORM, WITH CHECK ATTACHED, OR CREDIT CARD DETAILS COMPLETED** (US funds only) to:
PRA Destination Management Atlanta, by **Monday, May 14, 2007**. No refunds will be given for tickets after Monday, **Monday, May 14, 2007**.

Make checks payable to: **PRA Destination Management Atlanta,** 3525 Piedmont Road, Five Piedmont Center, Suite 300, Atlanta, GA 30305, USA
Tel. (404) 760-4229 • Fax (404) 264-1956

Tour tickets may be picked up at the Tour Registration Desk located in the GWCC registration area. ***Please indicate the quantity of tickets for each activity.***

Date/Time	Tour Title	Price per Person		Number of Persons		Amount Due per Tour
Sunday, June 17						
11:00 am-5:00 pm	Stone Mountain Park	$ 72.00	x	_____	=	$ _____
1:00 pm-5:00 pm	A Thirst for Atlanta	$ 49.00	x	_____	=	$ _____
Monday, June 18						
1:00 pm to 5:00 pm	Nobelists of Georgia	$ 39.00	x	_____	=	$ _____
5:30 pm to 10:00 pm	Welcome to Tara	$ 82.00	x	_____	=	$ _____
Tuesday, June 19						
9:30 am to 1:30 pm	From Page to Stage	$ 53.00	x	_____	=	$ _____
1:00 pm to 4:00 pm	Visit the CDC	$ 39.00	x	_____	=	$ _____
Wednesday, June 20						
9:30 am to 1:30 pm	Buckhead Homes and History	$ 47.00	x	_____	=	$ _____
1:00 pm to 4:00 pm	Visit the CDC	$ 39.00	x	_____	=	$ _____
				TOTAL # of TICKETS		**TOTAL AMOUNT DUE**
				_____	=	$ _____

Registrant's Name (please print) _____

Address _____

City _____ State _____ Zip/Postal Code _____ Country _____

Daytime Phone # _____ Fax # _____

eMail _____

PAYMENT (please check one):
Credit Card Type: ❑ Visa ❑ MasterCard ❑ American Express ❑ Check (payable to PRA Destination Management Atlanta, drawn on U.S. Bank only)

Card # _____ Expiration Date _____

Name on Card (please print) _____

Authorized Signature _____ V Code _____

WAIVER

Enclosed are funds in the amount of $ _____ as full payment for the Tour Program. I understand that this is non-refundable after **May 14, 2007**, unless the minimum number of participants required to operate the tour is not met. Neither **PRA Atlanta**, nor **DIA** is responsible for lost or damaged articles, traffic delays, accidents, strikes, riots, war, governmental action or regulation, acts of God, or other causes over which the parties have no control. In the event any or all of the Tours are canceled because of reasons beyond the parties' control, neither party shall incur any liability or obligation, and PRA Atlanta shall refund all deposits to participants. I further represent that I (and/or my children) am (are) in proper physical condition to participate in all requested activities and waive all claims for myself, my heirs, and assigns against Atlanta, DIA and all event sponsors and their representatives, successors, and assigns for any injury or illness which may result from my (or my children's) participation.

Signature of participant _____ Date _____

Completed Forms may be FAXED to (404) 264-1956 or follow the instructions on page 20 to register for tours online.

The Atlanta Housing Bureau will open for reservations on JANUARY 15, 2007.

Attendee Registration Form

ATTENDEES MAY REGISTER ONLINE AT WWW.DIAHOME.ORG | ONLINE REGISTRATION IS *NOT* AVAILABLE TO SPEAKERS OR EXHIBITORS.

43RD ANNUAL MEETING ID #07001 June 17-21, 2007, Atlanta, GA, USA

This registration form should be used by paying **ATTENDEES ONLY.** If paying by credit card, return this completed form to DIA by mail to 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA or by fax to +1-215-442-6199. If paying by check, follow instructions under Payment Methods below.

All registrations received at the DIA office in Horsham, PA, USA by 5:00 PM on May 11, 2007 will be included in the Advance Registration Attendee List.

PLEASE NOTE This page must be completed and submitted for each person attending any portion of this event.

PAYMENT METHODS REGISTER ONLINE AT www.diahome.org or check payment method:

❑ **CREDIT CARD** number may be faxed to: +1-215-442-6199.
You may prefer to pay by check or bank transfer since non-US credit card payment will be subject to the currency conversion rate at the time of the charge.

❑ VISA ❑ MC ❑ AMEX Exp. Date _____

Card # _____

Signature _____

❑ **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

❑ **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Meeting I.D. #07001 must be included on the transfer document to ensure payment to your account.

CANCELLATION POLICY

All cancellations must be in writing and be received at the DIA office by 5:00 PM on or before June 1, 2007. Registrants who do not cancel by June 1, 2007 and do not attend will be responsible for the full applicable fee. **Registrants are responsible for cancelling their own airline and hotel reservations.** You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. **Substitute registrants will be responsible for nonmember fee, if applicable.**

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants. Speakers and program agenda are subject to change. **Cancellations received in writing on or before June 1, 2007 will be processed as follows.**

FULL MEETING CANCELLATION	Government/Nonprofit/Academia – Registration fee paid minus $100 = Refund Amount All Others – Registration fee paid minus $200 = Refund Amount
NETWORKING RECEPTION CANCELLATION	On or before June 1, 2007 = Full Refund
TUTORIAL CANCELLATION	On or before June 1, 2007 – Registration fee paid minus $75 = Refund Amount
ONE-DAY REGISTRATION	There will be NO REFUNDS given for cancellations of one-day registrations or one-day no shows.

PARTICIPANTS WITH DISABILITIES DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs.

FULL-MEETING REGISTRATION (attendance of 2 or more days) includes admission to all scientific sessions, exhibits, coffee breaks, luncheons and receptions. ***If DIA cannot verify your membership upon receipt of registration form, you will be charged the nonmember fee. All fees are in US dollars.***

ONE-DAY ONLY REGISTRATION FEE Will be available closer to the meeting date at a cost of $690 for members and $820 for nonmembers.

TUTORIALS See pages 14-15 for the tutorial schedule. Space is limited and preregistration is encouraged. Please indicate the I.D# and fee for each tutorial you plan to attend.

Tutorial # _____ Fee _____

Tutorial # _____ Fee _____

Tutorial # _____ Fee _____ Tutorial Subtotal _____

PREREGISTRATION FEES ***A surcharge of $150 will apply to all registrations received after June 8, 2007.*** (does not apply to one-day registrations). Attendees will be required to produce their confirmation letter to avoid the $150 surcharge. To ensure that your registration is processed and sufficient time is allowed for receipt of confirmation letter, a completed registration form and payment must be received by the preregistration deadline of **June 8, 2007. An email address must be included below for confirmation process.**

Member Fee	**US $1150** ❑
Join DIA now to qualify for the member fee and to enjoy the benefits of membership for a full year! www.diahome.org	**US $ 130** ❑
Nonmember Fee	**US $1280** ❑

A one-year membership to DIA is available to those paying a NONMEMBER meeting registration fee. If paying a nonmember fee, please indicate if you do, or do not, want membership.

I do ❑ I do NOT ❑ want to be a DIA member

Discount Fees	**MEMBER**	**NONMEMBER***
Government (Full-time)	US $ 300 ❑	US $ 430 ❑
Charitable Nonprofit/Academia (Full-time)	US $ 675 ❑	US $ 805 ❑

*If paying a nonmember fee, please check one box above, indicating whether you want membership.

NETWORKING RECEPTION (Must be registered for meeting in order to attend) **US $70** ❑
Networking Reception Only is not available.

Applicable Meeting Registration Fee **US $** _____

Tutorial Registration Fee **US $** _____

Networking Reception Fee **US $** _____

TOTAL PAYMENT DUE **US $** _____

Last Name First Name MI

Degrees ❑ Dr. ❑ Mr. ❑ Ms.

Job Title

Company

Mailing Address

City State Zip/Postal Code Country

Telephone # Fax # email **(email address is required for confirmation)**

DIA
Drug Information Association
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595 USA

Add TUTORIALS and/or NETWORKING RECEPTION to an Existing Meeting Registration

DRUG INFORMATION ASSOCIATION

43RD ANNUAL MEETING ID #07001

June 17-21, 2007, Atlanta, GA, USA

This registration form should be used by attendees, speakers, track and session chairs, or exhibitors who wish to add Tutorials or the Networking Reception to an existing meeting registration, or by someone who wishes to register for Tutorials only.

If paying by credit card, mail this completed form to DIA, 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA or fax to +1-215-442-6199. If paying by check, follow instructions under Payment Methods.

PAYMENT METHODS: Please check payment method:

❑ **CREDIT CARD** number may be faxed to: +1-215-442-6199.
You may prefer to pay by check or bank transfer since non-US credit card payment will be subject to the currency conversion rate at the time of the charge.

❑ VISA ❑ MC ❑ AMEX Exp. Date _____

Card # _____

Signature _____

❑ **CHECK** drawn on a US bank payable to and mailed along with this form to:
Drug Information Association, Inc., PO Box 95000-1240, Philadelphia, PA, USA 19195-1240. Please include a copy of this registration form to facilitate identification of attendee.

❑ **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Meeting I.D. #07001 must be included on the transfer document to ensure payment to your account.

CANCELLATION POLICY

All cancellations must be in writing and be received at the DIA office by 5:00 PM on or before June 1, 2007. Registrants who do not cancel by June 1, 2007 and do not attend will be responsible for the full applicable fee. **Registrants are responsible for cancelling their own airline and hotel reservations.** You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. **Substitute registrants will be responsible for nonmember fee, if applicable.**

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants. Speakers and program agenda are subject to change. **Cancellations received in writing on or before June 1, 2007 will be processed as follows.**

FULL MEETING CANCELLATION	Government/Nonprofit/Academia – Registration fee paid minus $100 = Refund Amount All Others – Registration fee paid minus $200 = Refund Amount
NETWORKING RECEPTION CANCELLATION	On or before June 1, 2007 = Full Refund
TUTORIAL CANCELLATION	On or before June 1, 2007 – Registration fee paid minus $75 = Refund Amount
ONE-DAY REGISTRATION	There will be NO REFUNDS given for cancellations of one-day registrations or one-day no shows.

PLEASE NOTE: This page must be completed and submitted for each person attending any portion of this event.

❑ **YES,** I am registered for the meeting and I would like to add the Networking Reception and/or the following Tutorials to my registration. I am registered as:
❑ Attendee ❑ Speaker ❑ Track Chair
❑ Session Chair ❑ Exhibit Personnel

❑ **NO,** I do not wish to register for the meeting, but I would like to register for the following Tutorials.

TUTORIALS

See pages 14-15 in the online brochure for tutorial prices and schedule. Space is limited and preregistration is encouraged. Please indicate the I.D. # and fee for each tutorial you plan to attend.

Tutorial # _____ Fee _____

Tutorial # _____ Fee _____

Tutorial # _____ Fee _____ Tutorial Subtotal _____

Join DIA now to save on future meeting registration fees and to enjoy the benefits of membership for a full year! www.diahome.org US $ 130 ❑

NETWORKING RECEPTION (Must be registered for meeting in order to attend) US $70 ❑

Registration for Networking Reception Only is not available.

TOTAL PAYMENT DUE US $ _____

PARTICIPANTS WITH DISABILITIES
DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs.

Last Name First Name MI

Degrees ❑ Dr. ❑ Mr. ❑ Ms.

Job Title

Company

Mailing Address

City State Zip/Postal Code Country

Telephone # Fax # email **(email address is required for confirmation)**

EXHIBIT PERSONNEL REGISTRATION FORM

Online registration is *not* available to exhibit personnel.

Exhibitors should return this form to the attention of the Exhibits Department at DIA.

43RD ANNUAL MEETING ID #07001 June 17-20, 2007, Atlanta, GA USA

If registering for tutorials or the networking reception and paying by credit card, return this completed form to DIA by fax to **+1-215-442-6199** or by mail to 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA. If paying by check, follow instructions under Payment Methods below.

All registrations received at the DIA office in Horsham, PA, USA by 5:00 PM on May 11, 2007 will be included in the Advance Registration Attendee List.

Each 10' x 10' booth includes: one **(1) complimentary full-meeting registration and three (3) exhibit booth personnel registrations.**

Please fill out a separate form for each exhibitor registrant.

To expedite your registration, please check the appropriate category:

❑ **COMPLIMENTARY FULL-MEETING REGISTRATION** ❑ **EXHIBIT BOOTH PERSONNEL**

Once you have utilized the four (4) badges provided per each 10' x 10' booth, any additional personnel must register as an attendee (not as an exhibitor).

Log on to www.diahome.org and download the ATTENDEE Registration Form, complete and return it as per the instructions on the form.

PLEASE NOTE: This page must be completed and submitted for each person attending any portion of this event.

PAYMENT METHODS: Check payment method:

❑ **CREDIT CARD** number may be faxed to: +1-215-442-6199.
You may prefer to pay by check or bank transfer since non-US credit card payment will be subject to the currency conversion rate at the time of the charge.

❑ **VISA** ❑ **MC** ❑ **AMEX** Exp. Date _____

Card # _____

Signature _____

❑ **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association, Inc., PO Box 95000-1240, Philadelphia, PA, USA 19195-1240. Please include a copy of this registration form to facilitate identification of attendee.

❑ **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Meeting I.D. #07001 must be included on the transfer document to ensure payment to your account.

CANCELLATION POLICY All cancellations must be in writing and be received at the DIA office by 5:00 PM on or before June 1, 2007. Registrants who do not cancel by June 1, 2007 and do not attend will be responsible for the full applicable fee. **Registrants are responsible for cancelling their own airline and hotel reservations.** You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. **Substitute registrants will be responsible for nonmember fee, if applicable.**

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants. Speakers and program agenda are subject to change. **Cancellations received in writing on or before June 1, 2007 will be processed as follows.**

NETWORKING RECEPTION CANCELLATION
On or before June 1, 2007 = Full Refund

TUTORIAL CANCELLATION
On or before June 1, 2007 – Registration fee paid minus $75 = Refund Amount

FULL-MEETING REGISTRATION
(attendance of 2 or more days) includes admission to all scientific sessions, exhibits, coffee breaks, luncheons and receptions.

ONE-DAY ONLY REGISTRATION FEE
Will be available closer to the meeting date at a cost of $690 for members and $820 for nonmembers.

TUTORIALS
See pages 14-15 in the online brochure for the tutorial schedule and prices. Space is limited and preregistration is encouraged. Please indicate the I.D. # and fee for each tutorial you plan to attend.

Tutorial # _____ Fee _____

Tutorial # _____ Fee _____

Tutorial # _____ Fee _____ Tutorial Subtotal _____

Join DIA now to qualify for the member fee and to enjoy the benefits of membership for a full year! www.diahome.org **US $ 130** ❑

NETWORKING RECEPTION
(Must be registered for meeting in order to attend) **US $70** ❑
Registration for Networking Reception Only is not available.

TOTAL PAYMENT DUE US $_____

PARTICIPANTS WITH DISABILITIES DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs.

Last Name First Name MI

Degrees ❑ Dr. ❑ Mr. ❑ Ms.

Job Title

Company

Mailing Address

City State Zip/Postal Code Country

Telephone # Fax # email **(email address is required for confirmation)**

DIA Drug Information Association

800 Enterprise Road, Suite 200, Horsham, PA 19044-3595 USA